Gracell Biotechnologies Inc. (GRCL) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts GRCL Hot Sheet
Join SI Premium – FREE
Gracell Biotechnologies Inc. (NASDAQ: GRCL) reported Q4 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).
For earnings history and earnings-related data on Gracell Biotechnologies Inc. (GRCL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Marriott International (MAR) PT Lowered to $141 at Jefferies
- MFA Financial (MFA) Misses Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
